Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Biotechs Benefit From Pharma Deals And Dollars

This article was originally published in Scrip

Executive Summary

Big pharma companies may be under pressure to buy like-sized peers with late-stage clinical programs and marketed products, but several collaborations with and investments in biotechnology firms announced during the first few days of 2016 show that the world's largest drug makers also are focused on long-term prospects for their research and development pipelines.


Related Content

Deal Watch: Merck Digging Into Epigenetics With Proteros Partnership





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst